Gefitinib
Brand: Iressa (US/EU/IN)
Anticancer
EGFR Tyrosine Kinase Inhibitor
Pharmacokinetics
| Half-life | 48 hours |
| Tmax | 5 h |
| Bioavailability | 60 % (approx) |
| Protein Binding | 90 % |
| Volume of Distribution | 2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Reduced absorption with PPIs/H2 blockers. Avoid strong CYP3A4 inducers. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Rash, diarrhoea, hepatotoxicity
Contraindications:
Severe hepatic impairment
Precautions:
Avoid acid suppression therapy